Year-end Report January 1 - December 31, 2018

STOCKHOLM, Feb. 20, 2019 /PRNewswire/ -- "We summarize 2018 and conclude: RaySearch stands strong. Order intake rose by 19 percent and RayCare has been introduced into clinical use"

Johan Löf, CEO of RaySearch. Comments page 3.


For full-year 2018, order intake increased 19 percent to SEK 805 M (675) and net sales rose 7 percent to SEK 627 M (585). However, the operating margin declined to 15 percent (27), primarily due to changes in accounting policies that are deferring our revenue recognition. Without application of the new accounting policies, net sales would have risen 18 percent to SEK 687 M and the operating margin would have been 22 percent. The operating margin declined due to a scheduled increase in depreciation as well as a global market offensive, which involved a 24 percent increase in the average number of employees during 2018. Cash flow was significantly strengthened in the fourth quarter.


    --  Net sales SEK 219.4 M (205.0), of which revenues from
        RayStation®/RayCare® SEK 206.2 M (192.6)
    --  Profit after tax SEK 32.8 M (72.3) and earnings per share before/after
        dilution SEK 0.96 (2.11)
    --  Operating profit SEK 41.7 M (98.7)
    --  Cash flow SEK 56.8 M (34.6)
    --  Order intake SEK 294.9 M (239.1), of which
        RayStation/RayCare/RayCommand® SEK 283.2 M (228.8)
    --  Order backlog SEK 828.0 M (581.2) at the end of the period, of which
        RayStation/RayCare/RayCommand® SEK 777.5 M (523.6)


    --  Net sales SEK 627.2 M (585.1), of which RayStation/RayCare SEK 577.5 M
    --  Profit after tax SEK 78.5 M (117.6) and earnings per share before/after
        dilution SEK 2.29 (3.43)
    --  Operating profit SEK 94.5 M (159.7)
    --  Cash flow SEK 1.8 M (19.1)
    --  Order intake SEK 805.2 M (674.6), of which
        RayStation/RayCare/RayCommand® SEK 762.5 M (630.0)
    --  The Board of Directors proposes that no dividend be paid for 2018


    --  IFRS 15 Revenue from Contracts with Customers came into effect on
        January 1, 2018, and reduced the company's license revenue from
        RayStation and RayCare by 17 percent in the fourth quarter and 19
        percent for full-year 2018 compared with the previously applied
        accounting standard (IAS 18), see Notes 1-2. The accounting policy
        changes also had a negative impact on net sales and earnings in 2018.


    --  RayStation was selected by several leading cancer centers, including
        L'Hôpital Maisonneuve-Rosemont in Quebec, Canada, Rogue Valley Medical
        Center in the US, Kaoshiung Chang Gung Memorial Hospital in Taiwan and
        Centrum Onkologii Ziemi Lubelskiej in Poland. In addition, Raysearch
        secured a significant order for RayStation from a major radiotherapy
        machine manufacturer.
    --  Since October 8, 2018, RayCare together with RayStation have been used
        to plan and manage the treatment of patients at Provision CARES Proton
        Therapy Center in Nashville in the US. This marks the introduction into
        clinical use of RayCare.
    --  RaySearch and Canon Medical Systems Corporation entered into a
        collaborative agreement to integrate RayStation/RayCare with Canon
        Medical's imaging systems and advanced visualization solutions.
    --  RayStation 8B* was launched with machine learning and deep learning
        applications, a new module for evaluation of robustness of treatment
        plans and Monte Carlo dose computation for photons.
    --  RayCare 2C* was released with comprehensive improvements and new
        advanced workflow features as well as enhanced activity and order
    --  RaySearch expanded its product line-up with the RayCommand treatment
        control system and has secured an initial order from Advanced
        Oncotherapy (AVO) in the UK. Refer to page 10 for more details about


    --  RaySearch has won five orders for RayStation in the UK with a total
        order value of SEK 48 M.

The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 20, 2019 at 7:45 a.m. CET.

TELECONFERENCE CEO Johan Löf and CFO Peter Thysell will present RaySearch's year-end report for January-December 2018 at a teleconference on Wednesday, February 20, 2019 at 10:00 a.m. CET. To participate in the teleconference, call +46 8 22 90 90 (Sweden), +44 330 336 6027 (UK) or +1 719 325 2054 (US). The access code is 188791#. Please call a few minutes before the teleconference begins. The presentation will be held in English.


Johan Löf, President and CEO
Tel: +46-8-510-530-00

Peter Thysell, CFO
Tel: +46-70-661-05-59


RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to cancer centers all over the world and distributes the products through licensing agreements with leading medical technology companies. RaySearch's software is currently used by over 2,600 centers in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information about RaySearch is available at

This information was brought to you by Cision,c2745141

The following files are available for download:

  The full report

View original content:

SOURCE RaySearch Laboratories